Biogen Stays Steady As Alzheimer’s Programs Falter

Still reeling from aducanumab’s failure in Phase III Alzheimer’s trial, Biogen management played up the company’s progress toward diversification and the promise of its pipeline.

Risk Dial — Biogen's high-risk pipeline has investors concerned

During its 24 April earnings call, Biogen Inc. tried to redirect attention from the recent Phase III failure of its Alzheimer’s candidate aducanumab and onto the better-than-anticipated performance in the first quarter. But with a key patent for its blockbuster multiple sclerosis drug Tecfidera under challenge, competition coming for its spinal muscular atrophy treatment Spinraza and a high-risk pipeline, the pressure is on.

First quarter revenues of $3.49bn were up 11% quarter-over-quarter, and beat consensus 2%. First quarter GAAP earnings per share were...

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

10 Jun 2025

• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

29 May 2025

• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

28 May 2025

• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Metsera’s Amylin Analog Stars In Obesity Phase I

09 Jun 2025

• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.